Efficacy and safety of roflumilast in Japanese patients with bronchial asthma (20 to 70 y) (APTA-2217-05)
Study identifier:APTA-2217-05
ClinicalTrials.gov identifier:NCT00242307
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A confirmatory study of APTA-2217 in adult patients with bronchial asthma (A placebo-controlled double-blind comparative study)
Medical condition
Bronchial Asthma
Phase
Phase 2/3
Healthy volunteers
None
Study drug
Roflumilast
Sex
All
Actual Enrollment
450
Study type
Interventional
Age
20 Years - 70 Years
Date
Study Start Date: 01 May 2004
Primary Completion Date: 01 Sept 2006
Study Completion Date: 01 Jun 2007
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
TANABE SEIYAKU Co., LTD.
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
